Trials — EHA 2026
The primary artifact of this vault: one Markdown file per trial / readout. EHA 2026 is a clinical-readout meeting, so the unit of analysis is the trial — not the speaker, not the tool, not the company. Same per-trial schema as ASH 2026 and ASCO 2026; EHA adds an explicit European cooperative-group sub-axis (HOVON, GIMEMA, GELTAMO, GMLL, IFM, LYSA, NCRI) and an EBMT registry sub-axis on transplant / cellular therapy.
Status: Template + master index. Per-trial pages will be populated in two waves: (1) regular abstracts upon HemaSphere-supplement release on May 12, 2026, 15:30 CEST (tomorrow); (2) Late-Breaking Abstracts on June 2, 2026, 15:30 CEST. Pre-meeting stubs flagged *expected, subject to embargo* are sourced from company toplines, ASCO 2026 heme subset (May 29 – Jun 2), and analyst preview pieces; numbers can shift on the actual abstract reveal.
Per-trial template
Each trial file (e.g., epcore-nhl-2-update.md) follows this schema. Copy and fill:
# <Trial acronym / name> — <Drug regimen, indication, line>
> **Abstract:** <abstract #, e.g., LB1234 / Presidential Symposium S100 / Oral S567> · **Session:** <session name, date, time CEST, hall> · **Embargo:** <date>
## At a glance
- **Sponsor:** <pharma / cooperative group (HOVON, GIMEMA, GELTAMO, GMLL, IFM, LYSA, NCRI, etc.)>
- **PI / presenter:** <name, institution>
- **NCT ID:** <NCTxxxxxxxx>
- **Phase:** <1 / 1b / 2 / 2-3 / 3 / pivotal / registry>
- **Design:** <arms, randomization, blinding>
- **N:** <enrolled / analyzed>
- **Primary endpoint(s):** <PFS / OS / EFS / CR rate / MRD-neg / VOC-free / FVIII expression>
- **Comparator:** <SOC / placebo / active comparator / historical>
- **Indication:** <heme disease, subtype, biomarker / cytogenetic selection>
- **Line:** <frontline / 1L / 2L / 3L+ / maintenance / post-transplant / post-CAR-T>
## Headline result
<One paragraph. Numbers + HR + p-value if known. If pre-embargo, mark
`*expected per <company> topline <date>*` or `*pre-embargo per <analyst source>*`
or `*ASCO 2026 readout, EHA 2026 update expected*`.>
## Mechanism / class
<Drug class, target, prior approvals (FDA + EMA). For CAR-T: construct details
(costim domain, CD-target, manufacturing). For bispecifics: format (IgG-like, BiTE,
DART). For gene therapy: vector + payload. Cross-link to related AACR mechanism
sessions.>
## Discussant takeaway
<Named discussant + key framing once known. EHA discussant identity is itself
a signal — senior figures in the relevant European disease group set the
post-meeting narrative.>
## Practice-changing?
<Yes / no / pending, with rationale: ESMO / EHA guideline implications, EMA / CHMP
filing path, unmet need, prior SOC. For non-malignant heme: ESH / EHA guideline
path. Flag any EU-only or EU-first approval angles.>
## Cross-links
- **AACR 2026:** <related mechanism / poster / session, if applicable>
- **AACR 2025:** <prior-year mechanism work>
- **ASCO 2026:** <heme readout earlier in the year, if applicable>
- **ASH 2026:** <December update expected, if applicable — flag "EHA-first, ASH-update">
- **ESMO 2026:** <if heme readout was presented there>
- **Other EHA 2026 trials:** <same class, same disease>
- **JPM 2026 / 2027:** <sponsor presentation / deal>
## Sources
- EHA abstract (HemaSphere supplement): <URL or "pending May 12 release">
- Company press release: <URL>
- Trade-press recap: <OncLive / Healio / ASCO Post URL>
- ClinicalTrials.gov: <NCT URL>
- EU CTR (EudraCT) / CTIS: <URL, if applicable>
Master trial index (pre-meeting watch list)
Pre-meeting shortlist for stub creation. All entries below are pre-abstract-release, sourced from company pipelines + AACR 2026 mechanism sessions + ASCO 2026 heme subset + EHA 2025 / ASH 2025 prior-year readouts + analyst preview pieces — to be reconciled with the May 12, 2026 abstract drop and the June 2 LBA release. Result column entries marked italic are speculative / not yet disclosed.
Lymphoma — DLBCL + bispecifics
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status (pre-abstract-release) |
| EPCORE NHL-2 / -3 / -5 interim |
Genmab / AbbVie |
r/r DLBCL + 1L combinations |
1b/2 / 3 |
PFS / CR / durability |
2-yr interim of epco mono; 1L combination signal |
| GO29781 / glofit + Pola-R-CHP (SKYGLO) |
Roche |
1L DLBCL high-IPI |
3 |
PFS / EFS |
Interim topline tracking; ASH 2026 update expected |
| SUNMO / STARGLO follow-up |
Roche |
r/r DLBCL glofit + GemOx |
3 |
OS |
EHA tends to host SUNMO/STARGLO long-term |
| frontMIND interim |
Incyte / MorphoSys |
1L DLBCL high-IPI (tafa+lena+R-CHOP) |
3 |
PFS interim |
ASCO 2026 LBA7000 PFS+; EHA reconcile + ASH update |
| POLARIX 5-yr follow-up |
Roche |
1L DLBCL (pola-R-CHP) |
3 |
OS update |
Long-term durability |
Lymphoma — CLL + indolent
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| BRUIN CLL-321 European subset / pirtobrutinib |
Lilly |
covalent-BTKi-resistant CLL |
3 |
PFS |
Pivotal interim — Presidential Symposium candidate |
| GAIA / CLL13 follow-up |
German CLL Study Group |
frontline fit CLL |
3 |
MRD-neg / PFS |
Fixed-duration ven combos long-term |
| FLAIR long-term follow-up |
UK NCRI |
frontline CLL |
3 |
PFS / MRD |
Ibrutinib+ven vs FCR; ibr+ven vs ibr |
| MAJIC |
AbbVie / academic |
frontline CLL |
3 |
MRD-neg / PFS |
Acalabrutinib + ven fixed-duration |
| TRANSCEND CLL 004 follow-up |
BMS |
r/r CLL liso-cel |
1/2 |
DOR / OS |
2-3 yr durability European cohort |
| Mosunetuzumab FL long-term |
Roche |
r/r FL |
2 |
DOR |
5-yr durability |
Myeloma — CAR-T + bispecifics
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| CARTITUDE-4 long-term + CARTITUDE-5 interim |
J&J / Legend |
r/r MM / NDMM |
3 |
PFS / OS |
European-cohort durability + frontline pivot interim |
| KarMMa-3 long-term + KarMMa-9 interim |
BMS / 2seventy |
r/r MM / NDMM |
3 |
PFS |
Frontline ide-cel pivot interim |
| MajesTEC-3 / -5 interim teclistamab |
J&J |
r/r MM + 1L combos |
3 |
PFS |
ASCO 2026 readout, EHA interim, ASH long-term |
| MonumenTAL-3 interim talquetamab |
J&J |
r/r MM 1–3L |
3 |
PFS |
Pivotal interim |
| RedirecTT-1 / -2 update |
J&J |
EMD MM dual bispecific |
1b/2 |
ORR |
Dual bispecific (BCMA + GPRC5D) |
| IFM 2020-02 / HOVON-MM frontline |
IFM / HOVON |
NDMM |
3 |
PFS / MRD |
European cooperative-group frontline |
| Allogeneic BCMA CAR-T |
Allogene / Caribou / others |
r/r MM |
1 |
safety + ORR |
Class watch |
Acute leukemias — AML + ALL
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Revumenib AUGMENT-101 + combos (European) |
Syndax |
r/r KMT2A-r / NPM1-mut AML |
1/2 + combos |
CR / MRD |
Post-approval European real-world + combos with ven/aza |
| Ziftomenib KOMET-001 / -007 / -008 European |
Kura |
r/r NPM1-mut AML + frontline combos |
2 / 3 |
CR / OS |
Post-approval European cohort + frontline pivot interim |
| HOVON-AML / GMLL frontline maintenance |
HOVON / GMLL |
post-induction AML |
3 |
RFS / OS |
European cooperative-group venetoclax maintenance |
| FLT3 inhibitors evolution |
various |
FLT3-mut AML |
3 |
OS |
Gilteritinib, quizartinib follow-up; new TKIs European cohorts |
| Frontline IDH inhibitors (European) |
Servier / others |
IDH1/2-mut AML |
3 |
EFS / OS |
Ivosidenib, enasidenib, olutasidenib frontline — EMA-relevant |
| GRAALL / ALL CAR-T European |
GRAALL / academic |
r/r B-ALL |
3 + registry |
EFS / OS |
Adult ALL European pivot + brexu-cel real-world |
MDS / MPN
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Imetelstat post-approval European |
Geron |
lower-risk MDS, transfusion-dependent |
reg / 4 |
TI rate |
Post-IMerge European real-world; Nordic MDS Group cohort |
| COMMANDS European follow-up |
BMS / Acceleron |
lower-risk MDS ESA-naive luspatercept |
3 |
TI rate |
Long-term durability European subset |
| IDH inhibitors in MDS |
Servier |
IDH-mut MDS |
2/3 |
response |
Frontline + post-HMA European cohorts |
| Momelotinib / pacritinib MF European |
GSK / Sobi |
myelofibrosis |
3 / 4 |
symptom + anemia |
Post-approval European real-world |
| IPSS-M-guided transplant (EBMT) |
EBMT |
MDS frontline transplant decision |
registry |
OS |
EBMT registry IPSS-M cohort |
Cell and gene therapy — durability + access
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Exa-cel / Casgevy European real-world |
Vertex / CRISPR |
sickle cell + beta-thalassemia |
reg / 4 |
VOC-free / TI |
Post-approval European treatment-center early experience; Karolinska data prominent |
| Lovo-cel / Lyfgenia European |
bluebird bio |
sickle cell |
reg / 4 |
VOC-free |
EU access pathway; second-malignancy reporting |
| In-vivo base / prime editing for SCD |
Beam / Editas / Verve / Prime |
sickle cell (early phase) |
1 |
safety + edit efficiency |
Class watch — next gen |
| Roctavian (val-rox) European long-term |
BioMarin |
hemophilia A |
reg / 4 |
FVIII expression curve |
2–4 yr durability European cohort |
| Hemgenix (etranadez) European long-term |
CSL |
hemophilia B |
reg / 4 |
FIX expression curve |
2–4 yr durability European cohort |
| CAR-T 4–5-yr durability (axi-cel, liso-cel, cilta-cel, ide-cel) |
Kite / BMS / J&J |
r/r LBCL + MM |
reg / 4 |
DOR / PFS / SPM |
EBMT registry European cohort durability + SPM |
| Beta-thalassemia gene therapy long-term |
Vertex / bluebird |
TDT |
reg / 4 |
TI rate |
Casgevy + ex-betibeglogene post-approval European |
Non-malignant heme
| Trial |
Sponsor |
Indication |
Phase |
Endpoint |
Status |
| Mim8 / next-gen FVIIIa-mimetic |
Novo Nordisk |
hemophilia A (with / without inhibitors) |
3 |
bleed rate |
Post-FRONTIER pivot data; European cohort |
| Concizumab / fitusiran European follow-up |
Novo / Sanofi |
hemophilia A/B with inhibitors |
3 |
bleed rate |
Real-world + long-term European |
| Mitapivat in SCD / thalassemia |
Agios |
sickle cell / thalassemia |
2/3 |
Hb / VOC |
RISE UP and ENERGIZE follow-up |
| Etavopivat follow-up |
Novo Nordisk (ex-Forma) |
sickle cell |
3 |
Hb / VOC |
HIBISCUS pivot update |
| PNH C5 vs C3 inhibitor head-to-heads |
Alexion / Novartis / Apellis |
PNH |
3 |
hemoglobin / TI |
Pegcetacoplan, iptacopan, danicopan combos |
| Caplacizumab / rituximab iTTP follow-up |
Sanofi / academic |
iTTP |
3 / registry |
exacerbation rate |
Long-term European cohort |
| Factor XI inhibitors heme implications |
various |
thrombosis |
3 |
bleed / VTE |
Abelacimab, milvexian, asundexian — cardiology spillover |
Cross-cutting themes (for themes.md)
To synthesize across trials/ once populated:
- EHA-first → ASH-update lineage. Many trials get a phase-2 mature / phase-3 interim at EHA and a longer-follow-up update at ASH six months later. Map this lineage in
themes.md to identify which EHA 2026 readouts will set the ASH 2026 framing.
- European cooperative-group dominance. HOVON, GIMEMA, GELTAMO, GMLL, IFM, LYSA, NCRI studies that don't always travel to ASH. The European-only investigator network and the EMA / CHMP regulatory read-through.
- The "CAR-T tail" in European registries. EBMT registry data on axi-cel, liso-cel, cilta-cel, ide-cel European durability and SPM signal. Real-world vs pivotal-trial gap is the load-bearing curve.
- Bispecifics + CAR-T compete and combine — European edition. Sequencing data from European real-world (DLBCL: bispecific-after-CAR-T; MM: same). Class read-through to solid-tumor T-cell engagers (DLL3, B7-H3 — cross-link to lung / SCLC at ESMO).
- Menin / IDH / FLT3 mature in AML — European cohorts. Revumenib and ziftomenib post-approval European real-world; combinations with ven/aza, FLT3, IDH; frontline pivots. Cross-link to AACR 2026 menin / leukemia mechanism sessions.
- Gene therapy for SCD — European access + durability. Casgevy / Lyfgenia 2–3 yr European post-approval data; EMA approval status; Stockholm / Karolinska treatment-center experience. Payer access bottlenecks distinct from US.
- Red cell biology / non-malignant heme — EHA strength. Mitapivat, etavopivat, hemoglobinopathy gene therapy, PNH inhibitors — proportionally larger at EHA than at ASH.
- AACR ↔ EHA ↔ ASH mechanism-to-clinic continuity. Each EHA practice-changing trial traces to a 1–3 year prior AACR mechanism session and forward-projects to an ASH long-term update. Map the lineage in
themes.md.